Efficacy and safety of cyclophosphamide, doxorubicin, vincristine, and prednisone regimen with pegylated liposomal doxorubicin±rituximab in treating diffuse large B-cell lymphoma

Minerva Med. 2021 Apr;112(2):310-312. doi: 10.23736/S0026-4806.19.06236-0. Epub 2019 Jul 17.
No abstract available

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • China
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / pharmacokinetics
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Doxorubicin / analogs & derivatives
  • Doxorubicin / pharmacokinetics
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / metabolism
  • Middle Aged
  • Polyethylene Glycols / administration & dosage
  • Polyethylene Glycols / adverse effects
  • Polyethylene Glycols / pharmacokinetics
  • Prednisolone / administration & dosage
  • Prednisolone / adverse effects
  • Prednisolone / pharmacokinetics
  • Progression-Free Survival
  • Rituximab / administration & dosage
  • Rituximab / adverse effects
  • Rituximab / pharmacokinetics
  • Vincristine / administration & dosage
  • Vincristine / adverse effects
  • Vincristine / pharmacokinetics
  • Young Adult

Substances

  • liposomal doxorubicin
  • Polyethylene Glycols
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisolone

Supplementary concepts

  • VAP-cyclo protocol